Free Trial

INmune Bio (INMB) Competitors

INmune Bio logo
$1.89 -0.03 (-1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 0.00 (-0.26%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INMB vs. CHRS, BIOA, GNLX, CRBP, FBRX, DERM, FATE, PLX, IPHA, and TNXP

Should you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Coherus Oncology (CHRS), BioAge Labs (BIOA), Genelux (GNLX), Corbus Pharmaceuticals (CRBP), Forte Biosciences (FBRX), Journey Medical (DERM), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Innate Pharma (IPHA), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry.

INmune Bio vs. Its Competitors

INmune Bio (NASDAQ:INMB) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Coherus Oncology has a net margin of 125.90% compared to INmune Bio's net margin of 0.00%. Coherus Oncology's return on equity of 0.00% beat INmune Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
INmune BioN/A -120.62% -92.94%
Coherus Oncology 125.90%N/A -34.85%

INmune Bio has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Coherus Oncology has higher revenue and earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INmune Bio$10K5,023.62-$42.08M-$2.48-0.76
Coherus Oncology$266.96M0.76$28.51M$1.551.12

In the previous week, Coherus Oncology had 1 more articles in the media than INmune Bio. MarketBeat recorded 1 mentions for Coherus Oncology and 0 mentions for INmune Bio. Coherus Oncology's average media sentiment score of 0.67 beat INmune Bio's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company Overall Sentiment
INmune Bio Neutral
Coherus Oncology Positive

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 21.0% of INmune Bio shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

INmune Bio currently has a consensus target price of $18.00, indicating a potential upside of 852.38%. Coherus Oncology has a consensus target price of $4.51, indicating a potential upside of 159.34%. Given INmune Bio's higher probable upside, equities research analysts clearly believe INmune Bio is more favorable than Coherus Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INmune Bio
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.29
Coherus Oncology
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Coherus Oncology beats INmune Bio on 12 of the 17 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INMB vs. The Competition

MetricINmune BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$51.04M$3.48B$6.18B$10.69B
Dividend YieldN/A2.26%5.72%4.83%
P/E Ratio-0.768.2420.7722.98
Price / Sales5,023.62481.95579.80129.94
Price / CashN/A47.5937.5161.65
Price / Book1.3010.6612.476.59
Net Income-$42.08M-$52.56M$3.32B$276.14M
7 Day Performance1.07%4.97%1.87%0.01%
1 Month Performance-0.53%16.48%8.40%3.60%
1 Year Performance-63.51%14.95%63.49%32.76%

INmune Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INMB
INmune Bio
1.7809 of 5 stars
$1.89
-1.6%
$18.00
+852.4%
-62.4%$51.04M$10K-0.7610
CHRS
Coherus Oncology
4.1942 of 5 stars
$1.73
+3.6%
$4.51
+160.8%
+102.7%$194.10M$266.96M1.12330
BIOA
BioAge Labs
N/A$5.50
+2.8%
N/AN/A$191.80MN/A0.00N/A
GNLX
Genelux
1.0966 of 5 stars
$5.25
+3.6%
$20.33
+287.3%
+136.7%$191.51M$10K-6.1010News Coverage
Analyst Forecast
Gap Up
CRBP
Corbus Pharmaceuticals
4.2375 of 5 stars
$16.32
+5.0%
$45.43
+178.4%
-0.7%$190.45MN/A-3.4340Trending News
Analyst Forecast
FBRX
Forte Biosciences
2.8015 of 5 stars
$14.75
-3.4%
$68.00
+361.0%
+157.7%$189.85MN/A-0.915Analyst Downgrade
Short Interest ↑
DERM
Journey Medical
2.0268 of 5 stars
$7.00
-2.9%
$12.17
+73.8%
+18.1%$189.69M$56.13M-18.4290
FATE
Fate Therapeutics
4.1382 of 5 stars
$1.39
-15.0%
$3.30
+137.4%
-52.3%$188.56M$13.63M-0.96550
PLX
Protalix BioTherapeutics
2.1244 of 5 stars
$2.45
+3.8%
$15.00
+512.2%
+96.3%$188.17M$61.95M-18.85200
IPHA
Innate Pharma
2.0989 of 5 stars
$1.93
-4.9%
$6.50
+236.8%
+4.2%$187.13M$21.77M0.00220
TNXP
Tonix Pharmaceuticals
2.8065 of 5 stars
$20.06
-5.3%
$70.00
+249.0%
+10.2%$185.75M$10.09M-0.5150Short Interest ↑
Gap Down

Related Companies and Tools


This page (NASDAQ:INMB) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners